Cognitive and affective disorders associated to HIV infection in the HAART era: findings from the NeuroICONA study : Cognitive impairment and depression in HIV/AIDS. The NeuroICONA study.
Saved in:
| Title: | Cognitive and affective disorders associated to HIV infection in the HAART era: findings from the NeuroICONA study : Cognitive impairment and depression in HIV/AIDS. The NeuroICONA study. |
|---|---|
| Authors: | Starace, F. (AUTHOR), Bartoli, L. (AUTHOR), Aloisi, M. S. (AUTHOR), Antinori, A. (AUTHOR), Narciso, P. (AUTHOR), Ippolito, G. (AUTHOR), Ravasio, L. (AUTHOR), Moioli, M. C. (AUTHOR), Vangi, D. (AUTHOR), Gennero, L. (AUTHOR), Coronado, O. V. (AUTHOR), Giacometti, A. (AUTHOR), Nappa, S. (AUTHOR), Perulli, M. L. (AUTHOR), Montesarchio, V. (AUTHOR), La Gala, A. (AUTHOR), Ricci, F. (AUTHOR), Cristiano, L. (AUTHOR), De Marco, M. (AUTHOR), Izzo, C. (AUTHOR) |
| Source: | Acta Psychiatrica Scandinavica. Jul2002, Vol. 106 Issue 1, p20-26. 7p. |
| Subjects: | HIV infections, Cognition disorders, Affective disorders |
| Abstract: | Objective: To assess the natural story of HIV-associated affective and cognitive disorders and the relationship with clinical, pharmacological, immunological and behavioural factors. Method: A total of 395 HIV-positive patients, naive to Highly Active Antirectroviral therapy (HAART), with no severe psychiatric disorders have been enrolled in the Neuro-ICONA Study. All participants were administered a comprehensive data collection instrument including an addiction behaviour survey, a medical problem list, a psychiatric assessment, a validated neuropsychological test battery. Results: The global prevalence of cognitive impairment and of prominent depressive symptomatology were 17.9 and 15.5%, respectively. A significant difference in the prevalence of prominent depressive symptomatology was observed between patients in HAART and those not taking HAART(14.1 vs. 23.8%; P =0.05). Conclusion: Depressive and cognitive disorders affect a substantial proportion of HIV-seropositive subjects. The prevalence of prominent depressive symptomatology appears to significantly vary in relationship to the therapeutic protocol. [ABSTRACT FROM AUTHOR] |
| Copyright of Acta Psychiatrica Scandinavica is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | Objective: To assess the natural story of HIV-associated affective and cognitive disorders and the relationship with clinical, pharmacological, immunological and behavioural factors. Method: A total of 395 HIV-positive patients, naive to Highly Active Antirectroviral therapy (HAART), with no severe psychiatric disorders have been enrolled in the Neuro-ICONA Study. All participants were administered a comprehensive data collection instrument including an addiction behaviour survey, a medical problem list, a psychiatric assessment, a validated neuropsychological test battery. Results: The global prevalence of cognitive impairment and of prominent depressive symptomatology were 17.9 and 15.5%, respectively. A significant difference in the prevalence of prominent depressive symptomatology was observed between patients in HAART and those not taking HAART(14.1 vs. 23.8%; P =0.05). Conclusion: Depressive and cognitive disorders affect a substantial proportion of HIV-seropositive subjects. The prevalence of prominent depressive symptomatology appears to significantly vary in relationship to the therapeutic protocol. [ABSTRACT FROM AUTHOR] |
|---|---|
| ISSN: | 0001690X |
| DOI: | 10.1034/j.1600-0447.2002.02289.x |
